Skip to main content

12-20-2022 | Dapagliflozin | News


Dapagliflozin on way to EC approval for all heart failure

Author: Eleanor McDermid


medwireNews: The EMA’s Committee for Medicinal Products for Human Use has recommended extension of the dapagliflozin license to encompass all heart failure irrespective of the ejection fraction.

The sodium-glucose cotransporter 2 inhibitor was previously approved for people with symptomatic heart failure and a reduced ejection fraction, but the recent DELIVER trial demonstrated its efficacy in people with a preserved ejection fraction.

Dapagliflozin is also approved for treatment of type 2 diabetes in adults and children older than 10 years, and for treatment of chronic kidney disease.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group


Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »